-+ 0.00%
-+ 0.00%
-+ 0.00%

B of A Securities Maintains Buy on LENZ Therapeutics, Lowers Price Target to $29

Benzinga·03/25/2026 13:21:07
Listen to the news
B of A Securities analyst Jason Gerberry maintains LENZ Therapeutics (NASDAQ:LENZ) with a Buy and lowers the price target from $35 to $29.